Pursglove Geordan Garrett has been granted 100,000 restricted stock units by GridAI Technologies Corp. This significant award, effective as of October 26, 2026, is a part of the company's strategy to incentivize its board members, reflecting a common practice in the electric and other services sector.

The grant is notable as it not only recognizes Garrett's contributions to the company but also increases his total ownership stake to 140,000 shares. The restricted stock units vested in full on the date of the grant, allowing Garrett immediate access to the shares.

Background

GridAI Technologies Corp. operates in the electric and other services combined sector, with its business address located at 433 Plaza Real, Suite 275, Boca Raton, FL. The company has undergone several name changes in recent years, previously known as Entero Therapeutics, Inc., First Wave BioPharma, Inc., and AzurRx BioPharma, Inc. Its current CIK is 0001604191.

What the Filing Says

The SEC filing states, "On October 26, 2026, the Reporting Person was granted 100,000 additional restricted stock units under the Issuer's 2020 Omnibus Equity Incentive Plan, as amended, in recognition of service on the Board of Directors, which vested in full on the date of grant." This indicates a clear commitment from GridAI to reward its directors and align their interests with those of shareholders.

Impact

This grant may affect not only Garrett but also the broader shareholder base, as it emphasizes the importance of equity incentives in retaining key personnel. Such moves can enhance investor confidence in the company's leadership and strategic direction.

What's Next

The filing does not say what happens next.